drugset
Drugs / Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
last change Jun 2021 re-read 3 minutes ago

Allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Cell therapy

Developed for
COVID-19 · viral pneumonia
Investigated by
Belarusian State Medical University · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Trials 1

today NCT04382547 · Ph 1/2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04382547 May 2020 → Jun 2021 COVID-19, viral pneumonia Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Allogenic pooled olfactory mucosa-derived mesenchymal stem cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04382547 ↗
Modality Cell therapy “mesenchymal stem cells” NCT04382547 ↗
Route Intravenous “intravenous injection” NCT04382547 ↗